Table 1.

Quantification of severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2)-neutralizing antibodies in sera from convalescent plasma donors (cohort 1).

Patient No.	Age (y)	Patient Status	Disease Severity	Virus Detection (RT-PCR)	IgG Ratio	IgA Ratio	ND50 a	PVND50 b
								SARS-CoV-2	SARS-CoV-1	VSV G
1	45	Convalescent	Mild-Moderate	+ c	4.2	7.9	64	20	<10	<10
2	64			+	4.7	5.1	92	160	20	160
3	64			+	3.9	5.0	65	160	30	160
4	53			+	1.4	0.7	28	10	<10	<10
5	53			+	1.3	1.3	40	60	<10	<10
6	42			+	2.2	2.0	56	40	40	<10
7	49			+	2.2	4.4	65	160	80	<10
8	49			+	3.9	>8	210	380	50	15
9	49			+	1.7	>9	259	640	40	40
10	34			+	2.7	0.8	46	20	<10	<10
11	48			+	2.0	3.3	46	20	<10	10
12	48			+	1.6	4.7	28	25	<10	<10
13	34			+	7.2	3.3	130	80	<10	<10
14	38			+	1.0	6.8	320	400	40	<10
15	29			n.d. d	1.3	7.4	56	80	80	<10
16	27			+	3.3	>8	210	160	160	<10
17	53			−	2.4	1.3	<10	<10	<10	<10
18	46			+	2.3	2.7	65	100	<10	<10
19	47			+	1.3	0.1	40	40	<10	<10
20	26			+	3.3	4.2	56	55	10	<10
21	26			+	2.7	5.6	92	100	80	<10
22	75	Intensive medical care	Severe	n.d.	1.9	>9	960	640	640	<10
23	66			+	11.6	>8	1280	1280	640	<10
24	56			n.d.	13	>8	733	480	640	<10
25	59			n.d.	8.8	>9	450	546	560	<10

^a Neutralization dose 50% (ND50); ^b Pseudotype virus neutralization dose 50% (PVND50); ^c “+”, detected, “-“, not detected; ^d n.d., not determined.